We analyzed BCR::ABL1 expression at stop and in the first month after discontinuation in 168 chronic myeloid leukemia patients who stopped imatinib or 2nd generation tyrosine kinase inhibitors (2G-TKIs) while in sustained deep molecular response. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.